•  

Licenseable Technologies

MI’s Joel Liederman on CanadaAM to talk product development

Joel Liederman, vice-president of Physical Sciences, appeared on CanadaAM April 5, 2016 to talk about how to make a product. The interview is part of CanadaAM's "What's Next" segment on technology and entrepreneurship. He and host Beverly Thomson discussed the process for moving from a napkin to a prototype to a market-ready product, including market testing, prototyping, soliciting more customer feedback, and eventually product launch. "Marketing a product is a lot easier now than it used to be," said Liederman. "In the ... Read more

Ontario advancing nine medical research projects in cancer, heart disease and sleep apnea to market

Applications for next MSc PoP granting round being accepted until February 25, 2016 TORONTO (January 26, 2016) — Nine Ontario-based medical research projects built on great science with potential for significant economic impact are advancing a step closer to market entry thanks to funding from Ontario Centres of Excellence’s Medical Sciences Proof-of-Principle (MSc PoP) program. The projects range from cancer to heart disease to sleep apnea in children. Applications for the next MSc PoP granting round are open until March 4, 2016. To ... Read more

Top 10 Portfolio Stories for 2015

2015 created a flurry of activity for MaRS Innovation and our portfolio. As the holidays begin, here are our picks for the top 10 news stories from MI's portfolio in 2015. We look forward to more exciting developments in 2016. You may also have noticed we've refreshed our website and re-organized how we communicate about our work and services. We'd love to hear your thoughts: contact Elizabeth Monier-Williams. Top 10 MI Portfolio Stories for 2015 1.  ChipCare Corporation, a University of Toronto start-up company ... Read more

University of Toronto sperm selection technology featured in the Toronto Star

"In a project spearheaded by PhD candidate Reza Nosrati, U of T researchers are trying to learn more about the way sperm cells move — something that could benefit those using in vitro fertilization (IVF)," writes Daniel Otis in "Sperm show U of T researchers a new trick: slithering" published in the Toronto Star on November 13, 2015. MaRS Innovation is working with Professor David Sinton, Nosrati and the university's Innovations and Partnerships Office to commercialize the technology for the human sperm ... Read more

My Virtual Dream publishes PLOS study on Nuit Blanche results

Baycrest Heath Sciences' "My Virtual Dream," an innovative and interactive live performance experience at the intersection of science, art and music, is currently touring the installation with appearances in Amsterdam in May and more scheduled for Irvine, CA in October. MaRS Innovation is working with the Baycrest team to commercialize the technology behind the demonstration, known as the virtual brain. My Virtual Dream was featured in TechVibes on July 8 and in a PLOS blog published on August 14, 2015. “The Virtual Dream tour ... Read more

MI’s head of imaging technologies quoted on bioprinting in U.K.’s Financial Times

Fanny Sie, MaRS Innovation's head of imaging technologies, was quoted in Tanya Powley's article, "Printing whole organs remains a long way off," for the U.K.'s Financial Times on June 11, 2015, regarding the technology's potential to transform existing healthcare practices. MI does wish to note that the article inaccurately attributes the PrintAlive device's development to MaRS Innovation; MI is working with the University of Toronto inventing team, led by Dr. Axel Gunther, to commercialize the device. Here's a short excerpt: Bioprinting could save pharmaceutical ... Read more

Dr. Raphael Hofstein in Biotechnology Focus: It’s time to declare an end to Canada’s two research solitudes

Biotechnology Focus, a compendium of the Canadian life sciences industry, has published a guest column by Dr. Raphael Hofstein, MaRS Innovation's president & CEO, and Elizabeth Monier-Williams, director of marketing and communications. The article explores the way research focused on discovery and commercialization are often viewed or positioned as competitors within the funding ecosystem and the need to align their goals: The time of Canada’s French and English solitudes may be past, as Governor General Michaëlle Jean notably stated when she took office ... Read more

MaRS Innovation statement on the 2015 Federal Budget

TORONTO, ON (April 23, 2014) — MaRS Innovation congratulates the Federal Government’s deepened commitment to support Canadian research and innovation, particularly in the healthcare sector. In particular, the $42 million over five years dedicated to support the Canadian Centre for Aging and Brain Health Innovation at Baycrest Health Sciences, which includes $32 million in support from the Federal Economic Development Agency for Southern Ontario (FedDev). Baycrest is a founding member institution of MaRS Innovation. “As a Baycrest partner and long-time champions of the ... Read more

Sunnybrook forms new industry partnership to advance WaveCheck technology

Co-development agreement, brokered by MaRS Innovation, to advance ultrasound chemotherapy monitoring technology as clinical tool TORONTO (March 12, 2015) — Sunnybrook Health Sciences Centre and MaRS Innovation today announced a co-development agreement for WaveCheck, an ultrasound technology that transforms conventional equipment so that physicians can monitor a breast cancer tumour’s response to chemotherapy. This announcement was covered in Biotechnology Focus, Aunt Minnie.com (radiology blog), dotmed.com, Bio-Medicine.org, Bloomberg Business and Research Views. The partnership with GE Healthcare, brokered by MaRS Innovation, seeks to develop WaveCheck ... Read more

MaRS Innovation collaborating with Johnson & Johnson Innovation and Janssen to advance Cardiac, Diabetes and Depression technologies

TORONTO, Jan. 12, 2015  — MaRS Innovation, the commercialization agent for Ontario's 15 leading academic institutions, today announced that it has formed a research collaboration with Johnson & Johnson Innovation, LLC and its Canadian affiliate, Janssen Inc., to advance three technologies focused on cardiac, diabetes and depression, respectively. This announcement was covered in Lab Product News. "These three projects reflect the quality of innovation present in Toronto's research community for our industry partners, and Toronto's progress in addressing healthcare issues of international concern," ... Read more
Page 1 of 512345